Business
Timothy Scannell appointed to the Board
Timothy Scannell appointed to the Board.
About this update from Renalytix Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 5577G\n Renalytix PLC\n 30 March 2022\n \n \n \n \n \n \n \n Renalytix plc\n \n \n (\"Renalytix\" or the \"Company\")\n \n \n \n \n \n Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors\n \n \n \n \n \n \n NEW YORK and SALT LAKE CITY, March 30, 2022 - \n \n \n \n Renalytix Plc\n \n \n \n (NASDAQ: RNLX) (LSE: RENX)\n \n announces that, following the Company's announcement on February 22, 2022, Timothy Scannell has been appointed to the Board as an independent Non-Executive Director of Renalytix.\n \n \n \n \n \n \n As an accomplished leader in healthcare innovation, Mr. Scannell brings more than 30 years of experience in medical technology to the Renalytix Board, and previously served as President and C.O.O. of Stryker. Mr. Scannell currently serves as Chair of Insulet Corporation's board of directors and serves on the board of directors for Novocure and Collagen Matrix. He holds Bachelor of Business Administration and Master of Business Administration degrees from the University of Notre Dame.\n \n \n \n \n \n For further information, please contact:\n \n \n \n \n \n \n \n \n \n Renalytix plc \n \n \n \n \n \n www.renalytix.com\n \n \n \n \n \n \n \n James McCullough, CEO\n \n \n \n \n Via Walbrook PR\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Stifel (Nominated Adviser, Joint Broker)\n \n \n \n \n Tel: 020 7710 7600\n \n \n \n \n \n \n Alex Price / Nicholas Moore\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Investec Bank plc (Joint Broker)\n \n \n \n \n Tel: 020 7597 4000\n \n \n \n \n \n \n Gary Clarence / Daniel Adams\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Walbrook PR Limited\n \n \n \n \n Tel: 020 7933 8780 \n or \n \n \n [email protected]\n \n \n \n \n \n \n \n Paul McManus / Lianne Applegarth / Alice Woodings\n \n \n \n \n Mob: 07980 541 893 / 07584 391 303 / \n 07407 804 654\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n CapComm Partners\n \n \n \n \n \n Tel: 415-389-6400 \n \n or [email protected]\n \n \n \n \n \n \n Peter DeNardo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n AIM Rule Regulatory Disclosures\n \...